Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.

Leukemia research - 1 Mar 2010

Abulayha Abdulmunem M, Tabal Salah A, Shawesh Eman I, Elbasir Mohamed A, Elbanani Abdulrhman S, Lamami Yosra M, Bredan Amin

Abstract excerpt

The monoclonal antibody Rituximab is useful for treatment of patients with B-cell non-Hodgkin's lymphoma. We phenotypically analyzed reconstitution of peripheral B cells in a male patient with follicular lymphoma following their depletion with Rituximab. CD19+ and CD20+ B cell counts in peripheral blood decreased rapidly following Rituximab treatment. Six months after the end of treatment, a few CD19+ B cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to B-Lymphocyte Subsets

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B-Lymphocytes

Share to Cell Count

Share to Cell Separation

Share to Immunophenotyping

Share to Lymphoma, Follicular

Share to Rituximab

Source

Identifiers

PMID: 19580998
DOI: 10.1016/j.leukres.2009.06.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.PMID 19580998Read ↗

In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.Semantic proximity Read ↗

Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.Semantic proximity Read ↗

Depletion of functionally active CD20+ T cells by rituximab treatment.Semantic proximity Read ↗

A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.Semantic proximity Read ↗

Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.Semantic proximity Read ↗

Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission.Semantic proximity Read ↗

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.Semantic proximity Read ↗

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.Semantic proximity Read ↗

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.Semantic proximity Read ↗

A reservoir of rituximab-resistant splenic memory B cells contributes to relapses after B-cell depletion therapySemantic proximity Read ↗

Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.Semantic proximity Read ↗

Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.